Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XCEL-MT-OSTEO-ALPHA in non-union fractures
NCT02230514Phase 2Completed
- Sponsor
- Banc de Sang i Teixits
- Start
- Nov 2014
- Primary completion
- Mar 2019
- Modality
- Implantable Devices, Implantable Hydrogels, Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of XCEL-MT-OSTEO-ALPHA in fracture nonunion (2 arms), sponsored by Banc de Sang i Teixits. Primary endpoint: Efficacy assessment by imaging procedures at 12 months. Started Nov 2014; status: completed.
02
Drugs
XCEL-MT-OSTEO-ALPHA
03
Conditions
fracture nonunion
Beyond the preview
Go deeper on NCT02230514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02230514.